Company TrovaGene Inc Nasdaq
Equities
US8972384080
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapies for Cancers
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.42% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +26.42% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Chief Tech/Sci/R&D Officer | 67 | 23-01-30 | |
Vicki Kelemen
COO | Chief Operating Officer | - | 14-12-31 |
Charles Monahan
LAW | General Counsel | - | 22-01-10 |
Brigitte Lindsay
PRN | Corporate Officer/Principal | - | 11-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Lâle White
BRD | Director/Board Member | 68 | 20-04-21 |
Mani Mohindru
BRD | Director/Board Member | 52 | 21-06-09 |
Rodney Markin
CHM | Chairman | 67 | 14-02-18 |
Renee Tannenbaum
BRD | Director/Board Member | 72 | 21-06-09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 44,724,591 | 41,348,436 ( 92.45 %) | 0 | 92.33 % |
Stock B | 0 | 60,600 | 0 | 0 |
Company contact information
Cardiff Oncology, Inc.
11055 Flintkote Avenue
92121, San Diego
+858 952 7570
http://www.cardiffoncology.comSector
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |